THC Therapeutics Valuation
| THCT Stock | USD 0.0007 0.0001 16.67% |
THC Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of THC Therapeutics from evaluating the company fundamentals such as return on asset of -5.57, and Price To Earning of 1.25 X as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that THC Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of THC Therapeutics is based on 3 months time horizon. Increasing THC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
THC Therapeutics' intrinsic value may or may not be the same as its current market price of 0.0007, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.0E-4 | Real 6.72E-4 | Hype 6.4E-4 |
The intrinsic value of THC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence THC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of THC Therapeutics helps investors to forecast how THC pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of THC Therapeutics more accurately as focusing exclusively on THC Therapeutics' fundamentals will not take into account other important factors: THC Therapeutics Total Value Analysis
THC Therapeutics is at this time forecasted to have valuation of 1.57 M with market capitalization of 1.09 M, debt of 925.89 K, and cash on hands of 3.82 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the THC Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.57 M | 1.09 M | 925.89 K | 3.82 K |
THC Therapeutics Asset Utilization
One of the ways to look at asset utilization of THC is to check how much profit was generated for every dollar of assets it reports. THC Therapeutics owns a negative utilization of current and long term assets of -5.57 %, losing $0.0557 for each dollar of current and long term assets held by the company. Ineffective asset utilization indicates the company is being less capable with each dollar of current and long term assets it owns. Strictly speaking, asset utilization of THC Therapeutics shows how unsuccessful it operates for each dollar spent on its current and long term assets.THC Therapeutics Ownership Allocation
THC Therapeutics secures a total of 34.15 Million outstanding shares. THC Therapeutics shows substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company retains, if the real value of the company is less than the current market value, you may not be able to make money on it.THC Therapeutics Profitability Analysis
Net Loss for the year was (1.89 M) with profit before overhead, payroll, taxes, and interest of 0.About THC Therapeutics Valuation
The pink sheet valuation mechanism determines THC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of THC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of THC Therapeutics. We calculate exposure to THC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of THC Therapeutics's related companies.It is involved in the development of dHydronator, a sanitizing herb dryer for drying and sanitizing of freshly harvested cannabis, other herbs, flowers, and tea leaves. THC Therapeutics, Inc. was incorporated in 2007 and is based in Las Vegas, Nevada. Thc Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1 people.
8 Steps to conduct THC Therapeutics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates THC Therapeutics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct THC Therapeutics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain THC Therapeutics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine THC Therapeutics' revenue streams: Identify THC Therapeutics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research THC Therapeutics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish THC Therapeutics' growth potential: Evaluate THC Therapeutics' management, business model, and growth potential.
- Determine THC Therapeutics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate THC Therapeutics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
THC Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as THC Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 16.6 M | |
| Quarterly Earnings Growth Y O Y | -0.918 | |
| Retained Earnings | -36.5 M |
Additional Tools for THC Pink Sheet Analysis
When running THC Therapeutics' price analysis, check to measure THC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy THC Therapeutics is operating at the current time. Most of THC Therapeutics' value examination focuses on studying past and present price action to predict the probability of THC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move THC Therapeutics' price. Additionally, you may evaluate how the addition of THC Therapeutics to your portfolios can decrease your overall portfolio volatility.